A cellular analysis of long-term haematopoietic damage in mice after repeated treatment with cyclophosphamide.
AffiliationPaterson Laboratories, Christie Hospital, Manchester M20 9BX UK
MetadataShow full item record
AbstractFollowing repeated treatment of mice with cyclophosphamide (5 X 200 mg/kg) it was found that slight, but significant, residual marrow damage persisted for at least half the lifespan of the animals. This long-term damage occurred despite preferential sparing of those multi-potential haematopoietic cells (CFU-S) that had a high self-renewal capacity after each step of the multistep regimen and despite a smaller CFU-S kill after each successive dose. The damage was characterized by low mean numbers of CFU-S and stromal colony-forming cells (CFU-F) which were around 70% of control values. Examination of individual animals revealed that the majority had slightly subnormal numbers of CFU-S and CFU-F, with only a few suffering a more severe injury, including 8% of mice with clinical hypoplasia or myelodysplasia.
CitationA cellular analysis of long-term haematopoietic damage in mice after repeated treatment with cyclophosphamide. 1986, 18 (1):11-6 Cancer Chemother Pharmacol
JournalCancer Chemotherapy and Pharmacology
- Comparative in vitro effects of cyclophosphamide derivatives on murine bone marrow-derived stromal and hemopoietic progenitor cell classes.
- Authors: de Jong JP, Nikkels PG, Brockbank KG, Ploemacher RE, Voerman JS
- Issue date: 1985 Sep
- Interactions in recovery and in residual injury from sequential treatments of mouse haemopoietic and stromal marrow cell populations, using X-rays, cyclophosphamide and busulphan.
- Authors: Qi DY, Hendry JH, Testa NG
- Issue date: 1991 Jan
- Stem cell recovery from cyclophosphamide-induced myelosuppression requires the presence of CD4+ cells.
- Authors: Pantel K, Djuric Z, Nakeff A
- Issue date: 1990 Jun
- Late effects of chemotherapy on hematopoietic progenitor cells.
- Authors: Fried W, Adler S
- Issue date: 1985
- Response of hematopoiesis to cyclophosphamide follows highly specific patterns in bone marrow and spleen.
- Authors: Sefc L, Psenák O, Sýkora V, Sulc K, Necas E
- Issue date: 2003 Feb